When Warren Buffett handed the reins of Berkshire Hathaway to Greg Abel in January 2026, the investing world held its breath. Would the new CEO sell down the sprawling conglomerate? Fumble the legendary capital allocation machine? Barely six months in, the early answer is a quiet but decisive no — and Abel’s first moves signal something important for long-term shareholders.

The headline number is Berkshire’s $397–$398 billion cash pile, accumulated primarily under Buffett as equity valuations grew stretched. Abel isn’t letting it sit idle. Rather than building a stock portfolio, he is deploying capital into whole-company acquisitions — folding their earnings directly into Berkshire’s operating results. In Q1 2026, his first full quarter as CEO, operating earnings rose 17.7% year-over-year to $11.35 billion. Insurance underwriting profit surged 28.5%, and BNSF Railway delivered a solid recovery. These are the durable, compounding earnings engines Buffett spent 50 years assembling — and they are clearly accelerating under new management.

Abel’s acquisition fingerprints are already visible. He helped close the $9.7 billion OxyChem deal initiated under Buffett, and independently spearheaded the $6.8 billion acquisition of Taylor Morrison, the U.S. homebuilder. His stated preference: buy great businesses at fair prices, fold them into the Berkshire ecosystem, and let their cash flows compound quietly for decades. When he buys a company outright — rather than shares — shareholders benefit from 100% of its operating earnings, not just a percentage stake. At Berkshire’s scale, the math is powerful: a business generating $800 million annually at a 12x acquisition multiple creates compounding value that accrues directly to BRK shareholders with no drag from market volatility.

Berkshire shares have risen to an eight-month high in 2026, roughly in line with the S&P 500’s 9.6% gain year-to-date. But the more interesting story for patient investors is the Q2 2026 earnings report, the first summer report in Berkshire’s history without Buffett as CEO. Analysts and long-term watchers will scrutinize Abel’s capital allocation decisions, the pace of the cash drawdown, and whether insurance underwriting margins hold. Given Q1’s 28.5% surge in insurance underwriting profit, the underlying engine appears healthy.

For long-term investors, the transition at Berkshire deserves more attention than it has received amid the AI earnings frenzy. Abel is not reinventing the playbook — he is executing it with a subtle twist that actually improves the compounding math. Whole-company acquisitions generate more predictable, consolidated earnings than minority stock positions subject to market mark-to-market swings. With nearly $400 billion in dry powder and a management culture that has never chased trends, Berkshire may be one of the few large-caps positioned to compound shareholder value at a steady clip no matter what the market does next.

When Apple reported a record June quarter on July 30 — $109.4 billion in revenue, up 16% year over year, with earnings per share of $2.02 surging 29% — the market responded by sending shares down roughly 6%. The reason: management guided to only 9–11% revenue growth next quarter, citing “very significant” supply constraints on Mac memory and a gross margin step-down to 47–48%. Wall Street, conditioned for perpetual beats, sold first and asked questions later. Long-term investors should pay attention to the part of the story the market is ignoring.

The headline hiding beneath the noise is Apple’s Services segment. At $30.7 billion in quarterly revenue — up 12% year over year — Services now represents 28% of Apple’s total sales and is growing into a structurally higher-margin business every quarter. Apple set all-time records in cloud services and payment services during the quarter, and the company posted a consolidated gross margin of 50.1%, its best in decades. That figure included a roughly two-percentage-point boost from tariff refunds that likely won’t repeat, which is precisely why management guided margins lower for Q4. Strip out the one-time refund and the underlying margin expansion story remains intact. Apple’s gross margin was just 38% five years ago; today it sits above 50%, a transformation driven almost entirely by the Services engine attached to 1.4 billion active devices worldwide.

The leadership dimension adds another layer. Tim Cook closed his final earnings call — after 15 years at the helm — with a brief thank-you to investors and employees. His successor, hardware engineering veteran John Ternus, inherits a balance sheet with tens of billions in annual free cash flow, a buyback program that has retired roughly 40% of shares outstanding over the past decade, and a $0.27 quarterly dividend that has grown steadily since its 2012 reinstatement. For long-term investors, the transition risk is real but manageable: Ternus was Cook’s own choice, Apple’s product pipeline is multi-year in nature, and the installed-base moat deepens with every iPhone upgrade cycle regardless of who chairs the earnings call. The current 6% pullback — triggered by a one-quarter supply hiccup and a CEO handoff — is the kind of short-term noise that patient investors have historically been rewarded for looking through. A business compounding free cash flow at double-digit rates, with half-century gross margins and a Services flywheel that grows with every device sold, rarely trades at a discount for long.

When a company’s contracted future revenue grows 84% in a single year to $678 billion, that isn’t a headline — it’s a balance sheet for the next decade. Microsoft’s fiscal fourth-quarter 2026 results, released July 29, revealed exactly that: a business whose most important number isn’t the one Wall Street spent two days debating, but the locked-in demand backlog that virtually guarantees what comes after it.

The surface numbers were formidable enough. Total revenue hit $90.0 billion for the quarter, up 18% year-over-year, beating analyst estimates across the board. Azure and other cloud services grew 43% in Q4 — well ahead of the company’s own guidance — and crossed a milestone that no cloud business has reached before: $100 billion in annual revenue for fiscal 2026, up 41% from the $75 billion recorded the prior year. Intelligent Cloud as a whole generated $42.4 billion for the quarter. Microsoft’s operating income came in at $36.4 billion for the quarter, and the company returned $10.2 billion to shareholders in just those three months through dividends and share repurchases. For the full fiscal year, capital returned to shareholders totaled over $40 billion. Meanwhile, net income for the quarter received a meaningful boost from gains on Microsoft’s OpenAI and Anthropic investments — underscoring that its AI bets are beginning to compound in ways that even the income statement doesn’t fully capture yet.

The detail that should command the most attention from patient investors, however, is the commercial remaining performance obligations figure: $678 billion. That number represents signed, contracted enterprise deals that haven’t yet flowed through the income statement. It expanded 84% year-over-year, a pace that dwarfs revenue growth itself. To put it plainly: Microsoft’s customers are pre-committing to cloud and AI capacity years in advance, at a rate that suggests Azure’s $100 billion milestone is less a ceiling than a starting line. Management guided Azure growth of approximately 45% in constant currency for the first quarter of fiscal 2027, and guided H1 FY2027 growth to accelerate further — a statement almost no company of this scale has ever been able to make credibly. The price of that ambition is steep: capital expenditures reached nearly $116 billion for all of fiscal 2026, and FY2027 capex is guided between $255 billion and $260 billion. That number would represent the largest single-year infrastructure investment in corporate history. For short-term investors, the free cash flow math is uncomfortable. For long-term investors, it echoes precisely the period from 2010 to 2015 when Amazon was criticized for “burning cash” on AWS infrastructure that subsequently became the most profitable cloud business on earth.

For long-term investors, the case for Microsoft rests on a moat that is deepening faster than at any point in the company’s history. The $678 billion backlog is not speculative demand; it is signed contracts from enterprises that have chosen Azure as their AI infrastructure layer — a decision that is extraordinarily sticky once made. Microsoft’s integrated stack — Office 365, Teams, GitHub Copilot, Azure OpenAI Service, Dynamics, and Power Platform — means that every enterprise workload migration pulls multiple revenue streams behind it. The dividend, while modest at roughly 0.8% yield, has grown uninterrupted for over two decades and is backed by a business generating more than $100 billion in free cash flow annually. The risk is real: $255 to $260 billion in annual capex requires AI monetization to materialize at scale, and any slowdown in enterprise AI adoption would expose the spending cycle. But for investors with a five-to-ten-year horizon, Microsoft has accomplished something rare — it has built a contracted revenue runway that makes its future more legible, not less.

There is a phrase that long-term investors learn to cherish: accelerating revenue on a massive base. Amazon’s second-quarter 2026 earnings, released July 30, delivered exactly that. AWS grew 37% year over year — its fastest quarterly growth in 18 quarters — reaching $42.2 billion in revenue for the quarter alone. Annualized, that is a $169 billion run rate. For context, that single division would rank as a Fortune 100 company if it stood alone. Yet it is growing like a mid-cap startup.

The numbers across Amazon’s full business were equally striking. Total net sales hit $200.6 billion, up 20% year over year, while operating income surged 43% to $27.5 billion. Advertising revenue climbed 26% to nearly $20 billion — a line item that barely existed a decade ago and now rivals the market cap of many S&P 500 members. CEO Andy Jassy disclosed that Amazon’s AI services and custom silicon businesses — powered by its in-house Trainium chips — have each independently crossed a $25 billion annualized revenue run rate, both growing at triple-digit rates. Anthropic and OpenAI have made multi-year, multi-gigawatt Trainium commitments beginning in 2027, suggesting the pipeline is not slowing. Amazon is not just renting cloud compute — it is becoming the infrastructure layer of the AI economy.

Critics will note the risks. Amazon committed $200 billion in capital expenditures for 2026, and free cash flow on a trailing-twelve-month basis swung to an outflow of $7.6 billion as those investments hit the balance sheet. Short-term, the capex burn is real and investors should watch it. Long-term, however, this mirrors the playbook Amazon ran in 2014–2016, when heavy infrastructure investment was dismissed as reckless — and ultimately built the AWS moat that now generates tens of billions in annual operating profit. The pattern is familiar to those who study capital-intensive compounders: pain now, pricing power later.

For long-term investors, the key question is whether AWS’s growth rate is structural or cyclical. The evidence tilts structural. Enterprise cloud penetration globally still sits well below 50% of workloads. AI inference demand is additive to existing cloud spend, not a substitute for it. And Amazon’s integrated stack — compute, storage, databases, AI models, custom silicon, and advertising — creates switching costs that deepen with every workload migrated. The competitive moat here is not just scale; it is ecosystem lock-in across three distinct revenue engines (cloud, ads, retail) that reinforce one another. Patient investors who can tolerate the capex-heavy transition phase are looking at a business compounding at a pace that most single-asset portfolios cannot replicate.

When Procter & Gamble reported its fiscal year 2026 results on July 29th, the market fixated on the wrong number. Shares fell roughly 3% after net revenue of $87.0 billion came in slightly below Wall Street’s consensus estimate. But long-term investors who looked past the top-line miss found something far more instructive: a company that has now raised its dividend for 70 consecutive years, returned more than $15 billion to shareholders in a single fiscal year, and managed to grow core earnings per share to $6.89 — all in what management described as “a very challenging geopolitical and economic environment.”

The revenue miss matters less than the structural story underneath it. P&G’s organic sales grew 1% for the year, with sequential improvement accelerating into the back half of the fiscal year. The company generated robust operating cash flow to fund its $10 billion dividend payout — part of a $15 billion-plus capital return program — while simultaneously absorbing roughly $1 billion in headwinds from higher raw material, energy, and transportation costs. That management guided fiscal 2027 for 1%–3% organic sales growth despite those cost pressures signals the durability of the underlying franchise: 65 brands, sold in more than 180 countries, anchored in daily consumer necessities from Tide to Pampers to Gillette. These aren’t discretionary purchases that evaporate in a downturn. People wash their clothes, brush their teeth, and diaper their children regardless of the economic cycle.

The dividend record deserves more attention than it typically receives. P&G has paid a dividend without interruption for 136 consecutive years — every single year since its incorporation in 1890. It has raised that dividend for 70 straight years, placing it among an elite group of “Dividend Kings” that have hiked payouts through multiple recessions, wars, inflation spikes, and financial crises. An investor who bought P&G shares 20 years ago and reinvested dividends has seen those reinvested payouts compound into a meaningful portion of their total return. That compounding effect is invisible in a single quarterly earnings headline but becomes the dominant driver of wealth over a decade or two.

For long-term investors, the 3% pullback following yesterday’s results may be precisely the kind of entry point P&G rarely offers. At roughly 20 times earnings, the stock isn’t deeply cheap — but for a business with this level of brand moat, cash generation consistency, and 70-year dividend growth streak, paying a modest premium to own a piece of the compounding machine has historically proven worthwhile. The short-term market is reacting to a revenue line; the patient investor is watching a dividend that has been raised through every crisis of the past seven decades — and shows no sign of stopping.

The numbers coming out of Big Tech’s July earnings season look impressive — revenue beats, AI hype at full throttle, and market caps measuring in the trillions. But step back, and a quieter and more instructive story is unfolding in the data. The Magnificent Seven stocks are collectively trading at roughly 11 times sales and 70 times earnings. At the peak of the dot-com bubble in March 2000, the era’s five dominant technology giants — Microsoft, Cisco, Intel, Oracle, and IBM — traded at 11 times sales and 54 times earnings. That comparison is worth sitting with. Today’s AI leaders are more expensively priced than the companies that preceded one of the most brutal 20-year stretches in market history. Investors who bought those dot-com giants at the peak and held through the bust waited until 2020 — a full two decades — to merely break even.

The parallel isn’t meant to predict a crash. Markets can stay irrational longer than most people expect, and the underlying technology this time is genuine. The lesson isn’t “sell everything” — it’s about price. As InvestorPlace analyst Eric Fry pointed out this week, the dot-com leaders were right about the future; they were catastrophically wrong about the valuations investors assigned to that future. The same dynamic may be playing out today. Meta has now guided for $125 billion to $145 billion in capital expenditures for 2026, up from its prior range of $115 billion to $135 billion. Amazon, Alphabet, and Microsoft are spending similarly staggering sums, with an AI researcher at NYU calling it the “greatest capital misallocation in history” — spending at a rate of more than 12 times the Manhattan Project every single year. Meanwhile, the Philadelphia Semiconductor Index (SOX) is down more than 22% in July alone, its sixth-worst month on record, as questions about circular financing and AI demand sustainability catch up with the most crowded trade on Wall Street.

The rotation that follows boom peaks has a reliable historical pattern: the leaders of the previous cycle rarely lead the next one. In the years after the 2000 tech peak, the compounding came from energy, materials, financials, healthcare, and consumer staples — the “boring” sectors that had been starved of capital while everyone chased bandwidth stocks. Today, patient investors might find the same dynamic emerging. Healthcare stocks and financials have quietly outperformed tech in recent weeks, with Morgan Stanley upgrading quality-dividend names in both sectors. The S&P 500’s tech weighting sits near all-time highs even as earnings growth in non-tech sectors begins to accelerate. For long-term investors, the question isn’t whether to abandon growth entirely — it’s whether the valuations being paid for that growth leave any margin of safety. At 70 times earnings, the Mag 7 as a group prices in perfection. History suggests that, for patient capital, the better compounding opportunities are often found precisely where no one is looking: in the “boring” companies with reasonable valuations, durable cash flows, and the advantage of being invisible to the excitement-chasing crowd.

When a company triples its GAAP earnings per share year-over-year while simultaneously raising its dividend by 67%, long-term investors ought to take notice — especially when the stock has spent years out of favor. RingCentral (NYSE: RNG) delivered exactly that combination in its second-quarter 2026 earnings, and the market’s reaction — an 11% single-day gain capping a new four-year stock high — suggests the turnaround thesis may finally be gaining traction with institutional investors.

The numbers are worth examining in detail. RingCentral grew Q2 2026 revenue by 5.9% year-over-year to $657 million, with subscription revenues — the predictable, recurring engine of its business — rising 5.8% to $634 million and beating the company’s own guidance of $628–$633 million. More impressive was the earnings quality: GAAP diluted EPS came in at $0.45, more than tripling the $0.14 reported in Q2 2025. Non-GAAP EPS of $1.22 grew 15% year-over-year, also topping the company’s $1.15–$1.17 guidance range. Against this backdrop, management announced a first cash dividend of $0.125 per share — a 67% increase — payable to shareholders of record by August 6, 2026. That is not the action of a management team uncertain about cash flow durability.

The strategic pivot underpinning these results is worth understanding. RingCentral is repositioning itself as an “Agentic Voice AI” platform — using its proprietary global voice network and years of accumulated customer interaction data to orchestrate AI and human agents in enterprise contact centers. This is not a pivot away from its core cloud communications moat; it is a deepening of it. Businesses that have built workflows on RingCentral’s platform face meaningful switching costs, and the AI layer creates an additional wedge that could accelerate the revenue-per-seat expansion the company needs to sustain margin growth.

Institutional behavior adds texture to the thesis. While the total number of hedge funds holding RNG dipped slightly from 27 to 25 in Q1 2026, collective conviction strengthened markedly: the remaining holders grew their combined stake by 17.7%, from $344.8 million to $406 million. Fewer funds, but larger bets — a pattern that historically aligns with early-stage institutional accumulation rather than retreat.

For long-term investors, the RingCentral story is fundamentally about earnings quality catching up to what was always a defensible business. The company operates in a $40+ billion cloud communications and contact-center market where stickiness is high and enterprise churn is slow. A 67% dividend increase at this stage of its cash flow development signals management confidence that free cash flow generation is durable, not cyclical. Investors who let the stock languish through years of heavy investment and GAAP losses may be looking at a compounding setup now — one where improving fundamentals, a new income stream, and an AI narrative all converge at a price still well below the stock’s historical highs.

When a top executive at Johnson & Johnson sells nearly half her stake — $5.8 million worth of shares — the instinct is to read it as a fire alarm. But for patient investors who look past single transactions, the more important story at J&J right now is the transformation quietly compounding beneath the surface.

J&J’s Executive Vice President of Global Corporate Affairs, Vanessa Broadhurst, sold 23,054 shares on July 20th — roughly 50% of her holdings — with the stock already up 27% year-to-date. Bulls would call it routine profit-taking at an elevated price. Bears see it as a signal from someone inside the walls. The honest answer is that insider selling at record prices is common and rarely predictive on its own. What matters more is whether the underlying business justifies the valuation.

On that front, J&J’s latest results are hard to dismiss. Total revenue rose 6.6% year-over-year, with the oncology franchise up 17.3%. Darzalex — J&J’s flagship multiple myeloma treatment — grew nearly 18% and remains the company’s largest product. Carvykti, its next-generation cell therapy, posted 49.7% growth. Tremfya, used in psoriasis and Crohn’s disease, surged 72.5%, taking meaningful share from rivals. The company has effectively replaced the revenue erosion from Stelara, its older immunology blockbuster now facing biosimilar pressure — a feat that was far from guaranteed even two years ago.

The longer transformation story is structural. J&J spun off its consumer health division in 2023, separating Tylenol and Band-Aid from the higher-margin pharmaceutical and MedTech operations. It has since further streamlined by separating its orthopedics business into DePuy Synthes. The result is a more focused, higher-growth company guiding for 6% operational sales growth in 2026, backed by a deep pipeline including the OTTAVA soft-tissue surgical robot heading toward FDA review and multiple oncology candidates across myeloma and lung cancer.

For long-term investors, the central question is valuation. J&J currently trades at a forward P/E of roughly 21–22x, approximately 10% above the healthcare sector median. The dividend yield sits near 2.2%, lower than the historical average for an income name — reflecting the growth premium the market is now assigning. That is not obviously cheap, but it is not absurd for a business growing its highest-margin segment at double digits, holding a AAA credit rating, and sitting on a pipeline of drugs in high-growth therapeutic areas. The insider sale is worth noting. The compounding machine behind it is worth watching more closely.

While semiconductor stocks were grabbing headlines with a jaw-dropping 111% surge between late March and late June of 2026, a different story was quietly unfolding in two overlooked corners of the market. Healthcare and financial stocks — both trading at steep discounts to the S&P 500 — may represent the most compelling long-term value hiding in plain sight. For patient investors, the rotation now underway in AI hardware could be the signal worth acting on.

Richard Reyle, chief investment officer at Questar Capital Partners, which oversees $1.3 billion in assets, issued a pointed warning this week: mean reversion is coming for AI chip stocks. The iShares Semiconductor ETF has already fallen 18% from its June 22 peak, yet remains up 70% for 2026. Reyle draws a sobering analogy to the mid-2000s housing bubble, noting that it wasn’t a collapse in home prices that triggered the crisis — it was merely a deceleration in the rate of price increases. “It’s always the second derivative,” he told Business Insider. The same dynamic, he argues, now threatens memory makers and data center chip stocks. Warning signs are already blinking: Meta has begun selling excess compute capacity to other firms, a potential early indicator that AI infrastructure demand is topping out. Add cheaper AI models entering the market and the threat to chip earnings becomes harder to dismiss.

The flip side of this rotation is where long-term value investors should focus their attention. The healthcare sector currently trades at a forward price-to-earnings ratio of 17.9 — a meaningful 12% discount to the S&P 500’s 20.3x multiple. Reyle is particularly bullish on pharmaceutical stocks, citing Eli Lilly specifically as having roughly 25% upside potential driven by surging global demand for GLP-1 drugs like Mounjaro and Zepbound. Healthcare also carries a historically defensive profile, holding up better when broader economic momentum softens. Meanwhile, the financial sector — anchored by major banks posting record quarterly earnings — trades at an even steeper discount of 15.6x forward earnings. JPMorgan’s aggressive nationwide expansion of wealth management branches and Morgan Stanley’s record $148 billion in new assets during Q2 2026 underscore that the earnings engine in financials is accelerating, not fading.

For long-term investors, the lesson here is durable and familiar: the loudest trades are rarely the cheapest ones. When AI hardware commands 70%-plus gains in a single year, the asymmetric opportunity almost always lies elsewhere — in the sectors left behind. Healthcare’s defensive moat, GLP-1 tailwinds, and below-market valuation combine to offer genuine compounding potential over a multi-year horizon. Banks’ wealth management buildout, record earnings, and low P/E multiples tell a similar story. Neither sector requires a market collapse to deliver solid returns — they simply need the market’s attention to drift back toward fundamentals, which, historically, it always does. The compounders that are overlooked today have a way of becoming the winners that everyone wishes they had owned.

While Wall Street obsesses over AI chips and hyperscaler capex, two of America’s most recognizable logistics companies are quietly building durable, high-margin healthcare franchises — anchored by the explosive growth in GLP-1 medications and driven by infrastructure that most competitors simply cannot replicate overnight.

The numbers are striking. UPS generated its first-ever $3 billion healthcare revenue quarter in Q1 2026, a milestone CEO Carol Tomé highlighted on the April earnings call, noting the company’s global healthcare portfolio has gained market share every single year since 2021. The company followed that with a fresh $48 million investment in temperature-controlled facilities in June. FedEx, not to be outdone, launched a dedicated life sciences organization this month and disclosed that healthcare transportation revenue reached nearly $10 billion in fiscal year 2026 — a figure that would rank it among the largest standalone healthcare logistics businesses in the world. Meanwhile, DHL Supply Chain has committed 2 billion euros ($2.25 billion) to health logistics investment through 2030, with half directed to the Americas. The underlying market driving all of this: demand for temperature-sensitive biologics is projected to compound at 8.3% annually through 2033, reaching a market value of roughly $39.1 billion, per Growth Market Reports. GLP-1 adoption alone has surged from 3% of Americans in 2024 to 11% in 2026, per a July Gallup poll — and virtually all injectable GLP-1s require refrigerated cold-chain shipping from factory to patient.

What makes this particularly interesting for long-term investors is the moat geometry. Cold-chain healthcare logistics is not a business you improvise into. It requires dedicated aircraft lift, temperature-monitored warehousing networks, regulatory compliance across multiple jurisdictions, AI-driven predictive logistics (DHL is already using machine learning to anticipate cold-chain failures before they occur), and the operational credibility that global pharma companies demand when patient lives are at the end of every delivery. C.H. Robinson recently crossed $1 billion in healthcare logistics revenue largely on the back of GLP-1 demand — but it is the established players with integrated air networks, existing warehouse infrastructure, and decade-long pharma partnerships (UPS, FedEx, DHL) who are best positioned to lock in long-term contracts as the pharmaceutical industry outsources more of its cold-chain complexity. The FDA’s explicit warning that improperly stored GLP-1 drugs should not be used creates powerful liability incentives for pharma companies to stick with proven partners rather than shop on price.

For long-term investors, the takeaway is layered. First, UPS’s struggling core parcel business — pressured by Amazon’s logistics buildout and e-commerce softness — has obscured a healthcare division that is compounding quietly and gaining share in a structurally growing market. That healthcare revenue stream deserves a premium multiple relative to the commoditized parcel segment. Second, FedEx’s decision to formalize a life sciences organization signals a strategic commitment, not a tactical experiment. Third, the GLP-1 boom is still early: only 11% of Americans use these medications today, and global rollout across Europe and Asia is barely beginning. The cold-chain logistics capacity required to serve this market will be constrained for years — C.H. Robinson’s VP noted explicitly that refrigerated supply resources are “not unlimited.” Investors willing to hold through the near-term noise in the parcel and freight markets may find that the healthcare pivot at UPS and FedEx is the compounding engine hiding in plain sight inside two deeply familiar businesses.